Collaborations are a key part of Regeneron's strategy and mission
Regeneron has a long history of delivering breakthrough technologies and medicines, often aided by our history of highly successful collaborations with industry and academic partners.
We are always interested in new partnerships that will support our mission. Our Business Development and Preclinical Research teams welcome opportunities to engage in discussions related to:
- In-licensing and/or R&D collaborations to access important external innovation
- Licensing Regeneron’s platform technologies to leading academic groups and biopharma companies with the goal of maximize the value of these technologies by enabling others to discover important new medicines
- Learn more about VelocImmune® Licensing which provides research institutions with access to the VelocImmune mice for antibody discovery against biologic targets of their interest.
- Development and commercial partnerships with other leading biopharma companies in order to maximize the global potential of Regeneron’s pipeline
- External academic research collaborations to support academic research through access to Regeneron therapeutic candidates, animal models, cell lines and other technologies.
- Investigator Initiated Studies to support external investigators interested in studying Regeneron products and drug candidates in disease states of interest as well as epidemiological and other non-interventional studies focused on Regeneron’s areas of interest.
Why partner with Regeneron?
Regeneron offers prospective partners a unique home for your technology or therapeutic candidates through:
- Industry-leading technological expertise in core areas of antibody discovery, animal models, genetics research and biologics manufacturing
- The financial recourses and development and commercial capabilities of a fully-integrated biopharmaceutical company. Regeneron is developing one of the industry’s broadest pipelines and has recently executed one of the most successful biotech product launches in the industry’s history.
- An entrepreneurial culture rooted in our history as one of the industry’s longest-standing biotech companies that fosters the high-science mindset, nimble decision-making, and highly collaborative relationships
What external technologies are we looking for?
Because of Regeneron’s highly productive internal R&D organization, we maintain a “high bar” when evaluating any new external technologies or therapeutics. However, we believe it is important to follow the science and we have adopted a strategy that deliberately does not limit ourselves to any particular set of therapeutic areas. We are open to virtually any opportunity that 1) has the potential to offer important benefits to patients and represents a true scientific or medical advance and 2) Regeneron can make a real contribution toward bringing this innovation to patients.
In particular, we are interested in the following external technologies:
- Innovative technologies that could enable discovery of antibodies with superior therapeutic properties or against novel/challenging targets
- Technologies related to antibody-drug-conjugates or other approaches to enhancing activity of tumor-directed antibodies
- Diagnostics and technologies for biomarker discovery and validation that can be used to identify patients most likely to benefit from our antibodies
- Drug delivery or formulation technologies for our therapeutic proteins that can improve efficacy/safety profile, address a CMC or supply challenge, or enhance patient convenience or compliance
- Antibody or other biologic therapeutic candidates with first-in-class or best-in-class potential against targets that are of high priority to Regeneron.
"Regeneron is a terrific partner for their scientific leadership, as well as their product development capabilities and commercialization track-record."
- Thomas W. Chalberg, Ph.D., Co-founder and Chief Executive Officer of Avalanche Biotechnologies
Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA® (aflibercept) Injection for the treatment of eye disease by local administration. The companies share cost of development through an integrated global plan. Bayer has rights to market EYLEA outside the U.S., where the companies share equally in development costs and in profits from EYLEA sales. Within the U.S., Regeneron retains exclusive commercialization rights to EYLEA and is entitled to all profits from any future sales.
Antibody Discovery and Development
Since 2007, Regeneron has collaborated with Sanofi to discover, develop, manufacture and commercialize fully human monoclonal antibodies utilizing Regeneron's proprietary VelociSuite® of technologies. In the first three years of the collaboration, five antibodies entered clinical development.
The collaboration was expanded in 2009 with a goal of advancing 20-30 additional antibodies into clinical development by 2017. Under the terms of the expanded collaboration, Sanofi has agreed to provide $160 million in annual research funding through 2017. As part of the 2015 immuno-oncology collaboration outlined below, $75 million in aggregate over three years from the $160 million annual contribution will be ear-marked for the discovery and development of immuno-oncology antibodies.
Sanofi has the exclusive option to co-develop each drug candidate in the collaboration portfolio. Development costs are shared between the two companies, with Sanofi funding development costs up front and Regeneron reimbursing half of the development costs from its share of future profits. Regeneron has the right to co-promote all collaboration products worldwide. In the U.S., profits will be shared equally; outside the U.S., profits will be split on a pre-determined sliding scale.
Immuno-Oncology Discovery and Development
In 2015, Regeneron and Sanofi entered into a global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop Regeneron’s programmed cell death protein 1 (PD-1) inhibitor currently in Phase 1 testing (REGN2810) and plan to initiate clinical trials in 2016 with new therapeutic candidates based on ongoing, innovative preclinical programs.
This collaboration included upfront payments to Regeneron of $640 million, and the companies are investing $1 billion for discovery through proof of concept development of monotherapy and novel combinations of immuno-oncology antibody candidates to be funded 25 percent by Regeneron ($250 million) and 75 percent by Sanofi ($750 million). The companies are also equally funding an additional $650 million (or $325 million per company) for development of REGN2810, a PD-1 inhibitor. Finally, the two companies are re-allocating $75 million (in aggregate over in three years) for immuno-oncology antibodies from Sanofi’s $160 million annual contribution to their existing antibody collaboration, which otherwise continues through 2017. Beyond the committed funding, additional funding will be allocated as programs enter post-POC development.
As of an amended agreement dated February 2015, Sanofi is solely responsible for the development and commercialization of ZALTRAP for cancer indications worldwide. Sanofi bears the cost of all development and commercialization activities, and will reimburse Regeneron for its costs for any such activities. Sanofi also pays Regeneron a percentage of aggregate net sales of ZALTRAP during each calendar year (from 15% to 30%, depending on the aggregate net sales). Regeneron is responsible for the manufacture and supply of ZALTRAP and is paid by Sanofi for all quantities manufactured. Regeneron is no longer required to reimburse Sanofi for fifty percent of the development expenses that Sanofi funded for ZALTRAP under the Original Collaboration Agreement.
Astellas has a non-exclusive license to Regeneron’s VelocImmune technology for use in internal research programs to discover human monoclonal antibody products. The license was executed in 2007 and, in 2010, Regeneron and Astellas agreed to extend the license through 2023. Under the amended agreement, Astellas made a $165 million upfront payment to Regeneron in 2010 and will make another payment of $130 million in June 2018 unless Astellas terminates the agreement prior to that date.
Announced in 2014, Regeneron and Avalanche are collaborating on the development of novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular BioFactory™,an adeno-associated virus (AAV)-based platform. Avalanche has received an upfront cash payment and will receive contingent payments of up to $640 million upon achievement of certain development and regulatory milestones, plus a royalty on any potential worldwide net sales of collaboration products. The collaboration covers up to eight distinct therapeutic targets, and, as part of the agreement, Regeneron has a time-limited right of first negotiation for certain rights to AVA-101, Avalanche's gene therapy product targeting vascular endothelial growth factor (VEGF).
Regeneron Genetics Center Collaborators
Learn more about Regeneron Genetics Center Collaborators here.
Academic VIP Program
Under Regeneron’s Academic VelocImmune Investigators Program (Academic VIP), researchers at Columbia University Medical Center and The University of Texas Southwestern Medical Center at Dallas are provided with access to the VelocImmune technology platform. Scientists at these universities may use VelocImmune mice to generate antibodies against their research targets and conduct research to discover potential human therapeutics based on the antibodies. Regeneron has an exclusive option to license the antibodies for development and commercialization as therapeutic or diagnostic products.